One possible explanation relates to the findings of another study, which noted that the receipt of adjuvant FOLFOX for primary colorectal cancer may exert a selective pressure favoring a chemotherapy-resistant subset of disease enriched for KRAS mutations, while preventing liver recurrences for patients with KRAS wild-type primary tumors [26]. The gene discussed is KRAS; the disease is colorectal cancer.